Equillium is a preclinical to early-stage clinical biotechnology company developing targeted therapies for severe autoimmune and inflammatory disorders. The company's pipeline includes EQ504, a novel aryl hydrocarbon receptor modulator in preclinical development designed to reduce inflammation and support intestinal barrier function without broad immunosuppression, and EQ302, a first-in-class, selective bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery to address gastrointestinal and autoimmune conditions. The company targets large markets including ulcerative colitis and celiac disease, where significant unmet medical needs persist despite existing treatment options, and plans to generate revenue through regulatory approval and commercialization of these product candidates, potentially in partnership with established pharmaceutical companies.